VAYA Logo.png
CORRECTING and REPLACING -- Improved Academic Performance and Medication Rebound in Patients with ADHD Following the Use of Vayarin®, a Multi-Year, Real-World Retrospective Study
24. Januar 2017 13:03 ET | VAYA Pharma Inc.
BALTIMORE, Jan. 24, 2017 (GLOBE NEWSWIRE) -- In a release issued under the same headline January 10, 2017 by VAYA Pharma, please note that in the first paragraph under Results at a Glance, "38...
VAYA Logo.png
Improved Academic Performance and Medication Rebound in Patients with ADHD Following the Use of Vayarin®, a Multi-Year, Real-World Retrospective Study
10. Januar 2017 11:33 ET | VAYA Pharma Inc.
BALTIMORE, Jan. 10, 2017 (GLOBE NEWSWIRE) -- Up to 75 percent of individuals with Attention Deficit Hyperactivity Disorder (ADHD) experience emotional dysregulation, according to Research in...
robbins-llp-logo-white-background1583450-1.png
Robbins Arroyo LLP: Enzymotec Ltd. (ENZY) Stock Falls Nearly 40% After Violations of Federal Law are Revealed, According to Class Action
10. September 2014 20:36 ET | Robbins LLP
SAN DIEGO and MIGDAL HAEMEK, Israel, Sept. 10, 2014 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Enzymotec Ltd. (Nasdaq:ENZY) has filed a federal...